Advice

in the absence of a submission from the holder of the marketing authorisation:

emtricitabine / tenofovir disoproxil (Truvada®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of HIV-1 infected adolescents aged 12 to <18 years with nucleoside reverse transcriptase inhibitor resistance or toxicities precluding the use of first line agents.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.

Download detailed advice68KB (PDF)

Download

Medicine details

Medicine name:
emtricitabine/tenofovir disoproxil 200mg/245mg film-coated tablets (Truvada)
SMC ID:
1263/17
Indication:
Treatment of HIV-1 infected adolescents aged 12 to <18 years with nucleoside reverse transcriptase inhibitor resistance or toxicities precluding the use of first line agents.
Pharmaceutical company
Gilead Sciences Ltd
Submission type
Non submission
Status
Not recommended
Date advice published
10 July 2017